Anika Therapeutics Inc ANIK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $14.57
- Day Range
- $14.25–15.02
- 52-Week Range
- $7.87–16.24
- Bid/Ask
- $9.10 / $16.56
- Shares Outstanding
- 13.31M
- Market Cap
- $198.85M
- Volume/Avg
- 33 / 109,235
Key Statistics
- Price/Earnings (Normalized)
- 29.78
- Price/Sales
- 1.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 7.14%
Company Profile
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 235
- Website
- https://www.anika.com
Valuation
|
Metric
|
ANIK
|
|---|---|
Price/Earnings (Normalized) | 29.78 |
Price/Book Value | 1.46 |
Price/Sales | 1.78 |
Price/Cash Flow | 12.73 |
Price/Earnings
ANIK
Financial Strength
|
Metric
|
ANIK
|
|---|---|
Quick Ratio | 3.19 |
Current Ratio | 4.46 |
Interest Coverage | — |
Quick Ratio
ANIK
Profitability
|
Metric
|
ANIK
|
|---|---|
Return on Assets (Normalized) | 3.89% |
Return on Equity (Normalized) | 5.07% |
Return on Invested Capital (Normalized) | 3.38% |
Return on Assets
ANIK
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Djtfqfxd | Kzlrd | $69B | |||
| Haleon PLC ADR
HLN
| Wvmlmbwwr | Dtnp | $39B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Dvxnpjvxp | Wllmy | $39B | |||
| Zoetis Inc Class A
ZTS
| Qwqmhjxm | Hnzgn | $34B | |||
| Viatris Inc
VTRS
| Svsptjkc | Znq | $19B | |||
| Elanco Animal Health Inc
ELAN
| Xyxmz | Zbbnc | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Pzhnwcvl | Gpqtc | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Ktpmdkhhp | Qxzf | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| Ddbzbqvq | Gszkfp | $2B | |||
| Perrigo Co PLC
PRGO
| Ststlclpc | Hzyb | $2B |
United States